MAPT and Alzheimer disease: PET imaging of AD pathologic biomarkers such as Aβ and tau has been widely used for evaluating the pathologic features of AD, tracking AD progression, monitoring therapeutic interventions and facilitating drug development based on the ATN research framework [198].